Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Neuroendocrinology Letters

Volumn 25, Issue 1-2, 2004, Pages 31-39

  Russo, Ethan B ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

Allodynia; Analgesia; Cannabinoids; Cannabis; Causalgia; CBD; Fibromyalgia; Headache; Irritable bowel syndrome; Medical marijuana; Migraine; THC

Indexed keywords

ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABIS; ENDOCANNABINOID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; SEROTONIN;

ANTIINFLAMMATORY ACTIVITY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DATA BASE; FIBROMYALGIA; HUMAN; HYPERALGESIA; IRRITABLE COLON; MEDICAL RECORD REVIEW; MIGRAINE; NEUROIMAGING; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; REVIEW; PAIN; PHYSIOLOGY;

ARACHIDONIC ACIDS; CANNABINOIDS; ENDOCANNABINOIDS; FIBROMYALGIA; HUMANS; IRRITABLE BOWEL SYNDROME; MIGRAINE DISORDERS; PAIN; POLYUNSATURATED ALKAMIDES; SEROTONIN;

EID: 3242768538     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Freud S. Project for a scientific psychology. Trans. Strachey J. In: The standard edition of the complete psychological works of Sigmund Freud. Vol. 1, 24 vols. London: Hogarth Press.; 1966. p. 281-34 3.
2. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392:153-175.
3. Russo EB. Role of cannabis and cannabinoids in pain management. In: Weiner RS, editors. Pain management: A practical guide for clinicians. 6th edit., 2 vols. Boca Raton, FL: CRC Press; 2002. p. 357-375.
4. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63:569-611.
5. Russo EB. Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. Journal of Cannabis Therapeutics 2001; 1:21-92.
6. Russo EB. Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions. 2001. Haworth Press, Binghamton, NY.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949.
8. Herkenham MA. Localization of cannabinoid receptors in brain: relationship to motor and reward systems. In: Korman SG, Barchas JD, editors. Biological Basis of Substance Abuse. London: Oxford University; 1993. p. 187-200.
9. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231:313-314.
10. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sododemographic factors. Journal of the American Medical Association 1992; 267:64-69.
11. Lipton RB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. Neurology 1993; 43:56-10.
12. Russo E. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain 1998; 76:3-8.
13. Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 1985; 5:243-246.
14. Spadone C. Neurophysiologie du cannabis [Neurophysiology of cannabis]. Encephale 1991; 17:17-22.
15. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion. Journal of Neurophysiology 1995; 73: 907-910.
16. Boger DL, Patterson JE, Jin Q. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide. Proc Natl Acad Sci U S A 1998; 95:4102-4107.
17. Hall B, Burnett A, Christians A, Halley C, Parker LA, Russo E, et al. (2004). Pharmacology of cannabidiol at serotonin receptors. Western Pharmacology Society, Honolulu, HI.
18. Russo EB, Macarah CM, Todd CL, Medora R, Parker K. (2000). Pharmacology of the essential oil of hemp at 5HT1A and 5HT2a receptors. 41st Annual Meeting of the American Society of Pharmacognosy, Seattle, WA.
19. Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 1998; 21:224-226.
20. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache 1990; 30:5-11; discussion 24-18.
21. Peroutka SJ. Dopamine and migraine. Neurology 1997; 49:650-656.
22. Ferri S, Cavicchini E, Romualdi P, Speroni E, Murari G. Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology 1986; 89: 244-247.
23. Stefano GB, Salzet B, Rialas CM, Pope M, Kustka A, Neenan K, et al. Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 1997; 763:63-68.
24. Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial. J Clin Psychiatry 2003; 64:459-465.
25. Mülter-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 1999; 156:49 5.
26. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665-1669.
27. Burstein S. Eicosanoids as mediators of cannabinoid action. In: Murphy L, Bartke A, editors. Marijuana/Cannabinoids: Neurobiology and neurophysiology of drug abuse. Boca Raton: CRC Press; 1992. p. 73-91.
28. Evans AT, Formukong EA, Evans FJ. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 1987; 36:2035-2037.
29. Formukong EA, Evans AT, Evans FJ. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 1988; 12:361-371.
30. Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 1989; 41: 705-709.
31. McPartland J. Cannabis and eicosanoids: A review of molecular pharmacology. Journal of Cannabis Therapeutics 2001; 1:71-83.
32. Burstein S, Levin E, Varanelli C. Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol 1973; 22:2905-2910.
33. Schaefer CF, Brackett DJ, Gunn CG, Dubowski KM. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc 1979; 72:435-436.
34. Evans FJ. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med 1991; 57:560-67.
35. Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, et al. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1995; 1259:173-179.
36. Fimiani C, Liberty T, Aquirre AJ, Amin I, Ali N, Stefano GB. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat 1999; 57:23-34.
37. Fettes I, Gawel M, Kuzniak S, Edmeads J. Endorphin levels in headache syndromes. Headache 1985; 25:37-39.
38. Wiegant VM, Sweep CG, Nir I. Effect of acute administration of delta 1-tetrahydrocannabinol on beta- endorphin levels in plasma and brain tissue of the rat. Experientia 1987; 43:413-415.
39. Mailleux P, Vanderhaeghen JJ. Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen. Eur J Pharmacol 1994; 267:R1-3.
40. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395:381-383.
41. Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29:91-94.
42. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinodception. J Pharmacol Exp Ther 1991; 258:517-523.
43. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995; 46:575-605.
44. Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5- HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 1997; 36:535-542.
45. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 1998; 55:126-132.
46. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by the release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences 1999; 96: 12198-12203.
47. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353: 560.
48. Nicolodi M. Painful and non-painful effects of low doses of morphine in migraine sufferers partly depend on excitatory amino acids and gamma- aminobutyric acid. Int J Clin Pharmacol Res 1998; 18: 79-85.
49. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 1999; 90:1371-1376.
50. Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16:4322-4334.
51. Shen M, Thayer SA. Delta-9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1999; 55:8-13.
52. Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: Therapeutic and theoretic implications. Int J Clin Pharmacol Res 1995; 15:181-189.
53. Nicolodi M, Del Bianco PL, Sicuteri F. Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse. Int J Clin Pharmacol Res 1997; 17:97-100.
54. Nicolodi M, Sicuteri F. Negative modultors [sic] of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress. Int J Clin Pharmacol Res 1998; 18:93-100.
55. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95:8268-8273.
56. Main A, Dowson A, Gross M. Photophobia and phonophobia in migraineurs between attacks. Headache 1997; 37:492-495.
57. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 1999; 16:131-143.
58. McPartland JM, Russo EB. Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics 2001; 1:103-132.
59. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413:527-531.
60. Mikuriya TH. 1997. Chronic migraine headache: Five cases successfully treated with marinol and/or illiciit cannabis.
61. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. 1993. Yale University Press, New Haven.
62. el-Mallakh RS. Marijuana and migraine. Headache 1987; 27:442-443.
63. Gieringer D. Medical use of cannabis: Experience in California. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton, NY: Haworth Press; 2001. p. 153-170.
64. Gieringer D. Medical cannabis potency testing project. Bulletin of the Multidisciplinary Association for Psychedelic Studies 1999; 9: 20-22.
65. Bohr T. Problems with myofascial pain syndrome and fibromyalgia syndrome. Neurology 1996; 46:593-597.
66. Bennett RM. Rational management of fibromyalgia. Rheum Dis Clin North Am 2002; 28:xiii-xv.
67. Nicolodi M, Volpe AR, Sicuteri F. Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: Their common clues. Cephalalgia 1998; 18 (Suppl 21):41-44.
68. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319:R3-4.
69. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18:451-457.
70. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345:145-153.
71. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75:111-119.
72. Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J, et al. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999; 81:25-33.
73. Ko MC, Woods JH. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berl) 1999; 143:322-326.
74. Staud R, Vierck G, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91:165-175.
75. Strangman NM, Walker JM. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 1999; 82:472-477.
76. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
77. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429:177-193.
78. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134:845-852.
79. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48:859-867.
80. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 410-422.
81. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility sin mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134:563-570.
82. Anderson PF, Jackson DM, Chesher GB. Interaction of delta-9- tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol 1974; 26:136-137.
83. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003; 12:39-49.
84. Russo E. Cannabinoids in pain management. Study was bound to conclude that cannabinoids had limited efficacy. Brit Med J 2001; 323:1249-1250; discussion 1250-1241.
85. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003; 56:362-369.
86. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614-624.
87. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky D. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain 2003; 104:693-700.
88. Nicolodi M, Sicuteri R, Coppola G, Greco E, Pietrini U, Sicuteri F. Visceral pain threshold is deeply lowered far from the head in migraine. Headache 1994; 34:12-19.
89. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. In: Filippini GA, editors. Recent advances in tryptophan research. New York: Plenum Press; 1996. p. 373-379.
90. Peres MF, Young WB, Kaup AO, Zukerman E, Silberstein SD. Fibromyalgia is common in patients with transformed migraine. Neurology 2001; 57:1326-1328.
91. Hudson JI, Goldenberg DL, Pope HG, Jr., Keck PE, Jr., Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992; 92:363-367.
92. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999; 94:3541-3546.
93. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76:189-199.
94. Jaggar SI, Sellaturay S, Rice AS. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 1998; 253:123-126.
95. Brady CM, DasGupta R, Wiseman OJ, Berkley KJ, Fowler CJ. (2001). Congress of the International Association for Cannabis as Medicine, Berlin, Germany.
96. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105:223-230.
97. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404:84-87.
98. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362:1517-1526.
99. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003; 17:18-26.
100. Ferrari F, Ottani A, Giuliani D. Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. Physiol Behav 2000; 69: 547-554.
101. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmonds S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies. Anaesthesia 2004; 59:440-452.
102. Jarvinen T, Pate D, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95:203.
103. Russo E. Cannabis treatments in obstetrics and gynecology: A historical review. Journal of Cannabis Therapeutics 2002; 2:5-35.
104. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66:101-121.
105. Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976; 31:720-723.
106. Fride E. Cannabinoids and cystic fibrosis: A novel approach. Journal of Cannabis Therapeutics 2002; 2:59-71.
107. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998; 30:171-177.
108. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418:530-534.
109. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 2002; 452:295-301.
110. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003; 307:129-137.
111. Delgado P, Moreno F. Antidepressants and the brain. Int Clin Psychopharmacol 1999; 14 Suppl 1:S9-16.
112. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurology 2003; 2:291-298.
113. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002; 8:58-61.
114. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3:745-755.
115. Maccarrone M, Finazzi-Agro A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 2003; 10:946-955.
116. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003; 140:802-808.
117. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301:1020-1024.
118. Russo EB. Cannabis-From pariah to prescription. Journal of Cannabis Therapeutics 2003; 3(3):1-29.
119. Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. Journal of Cannabis Therapeutics 2001; 1: 183-205.
120. Whittle BA, Guy GW, Robson P. Cannabis and cannabinoids as medicines. 2003. Pharmaceutical Press, London.